Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5012779 | 0.82 | TRPV6 (0.48) | — | |
| SCHEMBL5015830 | 0.81 | LMNA (0.45) | — | |
| SCHEMBL5128958 | 0.81 | LMNA (0.45) | — | |
| SCHEMBL14033840 | 0.81 | RAB9A (0.54) | — | |
| SCHEMBL5124973 | 0.81 | RAB9A (0.54) | — | |
| SCHEMBL5116128 | 0.81 | RAB9A (0.54) | TRPV1 | |
| SCHEMBL5011078 | 0.79 | USP2 (0.47) | — | |
| SCHEMBL5129892 | 0.79 | GPR183 (0.46) | — | |
| SCHEMBL5130505 | 0.78 | MAPT (0.39) | TRPV1 | |
| SCHEMBL5125782 | 0.78 | GPR183 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888596-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2014-10-22 | — | — | EP | claimed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | claimed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | INA, SCN1A, SI | ACHE 21/4885TRPV1 57/4885BCHE 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.